First FDA-Approved Digital Pill Tracks Schizophrenic Patients
The FDA has approved the first pill with an embedded ingestible sensor that can track when, or if, a patient takes their medication.
Teodora Zareva is an entrepreneur, writer, board games geek and a curious person at large. Her professional path has taken her from filmmaking and photography to writing, TEDx organizing, teaching, and social entrepreneurship. She has lived and worked in the U.S. and Bulgaria and is currently doing her MBA at Saïd Business School at the University of Oxford. Her biggest passion lies at the intersection of media and youth development. She is the co-founder of WishBOX Foundation, a Bulgarian NGO that helps high school students with their professional orientation by organizing events, courses, summer camps and developing digital media resources.
The FDA has approved the first pill with an embedded ingestible sensor that can track when, or if, a patient takes their medication. The sensor will be used with the drug Abilify MyCite—which is prescribed to treat schizophrenia, bi-polar disorders and depression—and automatically shares data with doctors, caregivers, family members or anyone else the patient has pre-approved.
The sensor attempts to solve the problem of nonadherence. As it turns out, millions of patients don’t take their medications as prescribed, which leads to poor therapeutic outcomes and costs billions per year in avoidable health care costs. Ameet Sarpatwari, an instructor in medicine at Harvard Medical School, said for The New York Times that the digital pill “has the potential to improve public health,” especially for patients who want to take their medication but forget.
On the flip side, the constant monitoring may actually increase mistrust or make patients feel uncomfortable. Dr. Peter Kramer, a psychiatrist referred to the drug as “packaging a medication with a tattletale.”
Here’s how the ingestible sensor works with the drug. The sensor is the size of a “grain of sand” and is embedded within the pill at the point of manufacture. In addition to taking the pill, the patients are also required to wear a patch on their skin, which acts as an external sensor. The patch reads the signals sent from the ingested sensor, which is activated after the pill has interacted with stomach fluids. The information is then sent from the patch to an app installed on the patient’s phone. The patient can share (or stop sharing at any time) this information with others.
Ironically, the FDA notes on their website that “the ability of the product to improve patient compliance with their treatment regimen has not been shown.” The choice of drug (one that treats schizophrenia) to feature the first sensor of this kind may also raise some eyebrows. As Dr. Jeffrey Lieberman, chairman of psychiatry at Columbia University and NewYork-Presbyterian Hospital, said:
“There’s an irony in it being given to people with mental disorders that can include delusions. It’s like a biomedical Big Brother.”
Still, the technology could have other potentially beneficial applications. It could be used, for example, in clinical trials to make sure that participants are following protocols correctly. It could also be used to track excessive opioid use - a problem that has been on the rise in the U.S.
In more controversial applications, taking a pill like this could be a requirement for releasing patients with certain type of psychiatric disorders. It is also not a stretch to see that insurers may take an interest in it and provide incentives to customers who use it.
The famed author headed to the pond thanks to Indian philosophy.
- The famed author was heavily influenced by Indian literature, informing his decision to self-exile on Walden Pond.
- He was introduced to these texts by his good friend's father, William Emerson.
- Yoga philosophy was in America a century before any physical practices were introduced.
Pfizer's partnerships strengthen their ability to deliver vaccines in developing countries.
- Community healthcare workers face many challenges in their work, including often traveling far distances to see their clients
- Pfizer is helping to drive the UN's sustainable development goals through partnerships.
- Pfizer partnered with AMP and the World Health Organization to develop a training program for healthcare workers.
A little goes a long way.
- A recent study from the Department of Health and Human Services found that 80 percent of Americans don't exercise enough.
- Small breaks from work add up, causing experts to recommend short doses of movement rather than waiting to do longer workouts.
- Rethinking what exercise is can help you frame how you move throughout your day.
SMARTER FASTER trademarks owned by The Big Think, Inc. All rights reserved.